SCHEMBL869844

SCHEMBL869844

C1CCSCCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2550145 0.97
SCHEMBL5677378 0.97 CXCR4 (0.44)
Thiomorpholine SCHEMBL6624599 0.94 ALDH1A1 (0.53)
Pyrrolidine SCHEMBL14809175 0.94 ALDH1A1 (0.53)
SCHEMBL29016828 0.94 ALDH1A1 (0.53)
Piperidine SCHEMBL28519094 0.90 ALDH1A1 (0.60)
SCHEMBL12100700 0.90
SCHEMBL12882833 0.90 CXCR4 (0.41)
SCHEMBL138572 0.90
SCHEMBL11392517 0.90 ALDH1A1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4676960-B2 2011-04-27 JP claimed
JP-2006528940-A 2006-12-28 JP claimed
EP-1633746-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2006-03-15 EP claimed
WO-2004101554-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO claimed
EP-1479677-A1 New indole derivatives as factor xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2004-11-24 EP claimed
US-20240360156-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-10-31 US disclosed
US-12012467-B2 Small molecule DCN1 inhibitors and therapeutic methods using the same REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-06-18 US disclosed
US-20230058670-A1 NOVEL CELLULAR PHENOTYPE SCREENING METHOD THINKCYTE, INC. (JP) 2023-02-23 US disclosed
EP-3609876-B1 COVALENT SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME UNIV MICHIGAN REGENTS (US) 2022-03-30 EP disclosed
US-11279713-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-03-22 US disclosed
US-20200317692-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-10-08 US disclosed
US-10654874-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-05-19 US disclosed
US-20050107372-A1 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators LANTER JAMES C (US) 2005-05-19 US disclosed
US-6858621-B2 2-(quinolonyl)-fused heterocycles as androgen receptor modulators ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-02-22 US disclosed
US-20050033049-A1 Indole derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-02-10 US disclosed
EP-1501835-A2 2-(QUINOLONYL)-FUSED HETEROCYCLES AS ANDROGEN RECEPTOR MODULATORS Ortho-Mcneil Pharmaceutical, Inc. (US) 2005-02-02 EP disclosed
WO-2004101554-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO disclosed
EP-1479677-A1 New indole derivatives as factor xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2004-11-24 EP disclosed
US-20040014743-A1 2-(Quinolonyl)-fused heterocycles as androgen receptor modulators ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-01-22 US disclosed
WO-2003090672-A2 2-(QUINOLONYL)-FUSED HETEROCYCLES AS ANDROGEN RECEPTOR MODULATORS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2003-11-06 WO disclosed